Singapore Eye Research Institute   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Singapore Singapore (1997)

Organization Overview

First Clinical Trial
2008
NCT00607685
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Senior Consultant | Singapore Eye Research Institute | Singapore National Eye Centre, Singapore Eye Research Institute | Singapre national eye centre

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cicatrix (Phase 4)

Coronavirus Infections (Phase 3)

Cytomegalovirus Infections (Phase 4)

Glaucoma (Phase 3)

Glaucoma, Angle-Closure (Phase 3)

Hypertension (Phase 2)

Iridocyclitis (Phase 4)

Keratoconus (Phase 3)

Ocular Hypertension (Phase 2)

Severe Acute Respiratory Syndrome (Phase 3)

Uveitis (Phase 4)

Uveitis, Anterior (Phase 4)

Xerophthalmia (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 12
  • # of Trial APIs: 18